Browsing Tag
clinical trials
129 posts
Unicycive (NASDAQ: UNCY) hit by FDA manufacturing concerns ahead of oxylanthanum carbonate decision
Unicycive’s NDA for oxylanthanum carbonate faces FDA manufacturing concerns. Key decision expected June 28. Read the stock outlook and next steps.
Recursion Pharmaceuticals (NASDAQ: RXRX) stock rises after 20% workforce cut and pipeline reset
Recursion Pharmaceuticals (NASDAQ: RXRX) cuts 20% of workforce to extend runway and narrow pipeline focus—read what this means for its AI drug discovery strategy.
FPT advances digital healthcare strategy in Vietnam with AI-led public-private model
FPT Corporation launches AI-driven PPP framework to transform Vietnam’s healthcare system, aligning with Vision 2045 goals and digital health policy targets.
Can AI trial matching close the gap in cancer drug access?
Can AI fix clinical trial access in cancer care? Discover how Tempus, TrialJectory, and CureMatch are using intelligent platforms to democratize treatment pathways.
Q32 Bio’s bempikibart shows signs of a remittive effect in alopecia areata—Here’s what that means
Q32 Bio Inc. has released promising SIGNAL-AA trial results, shedding new light on the potential of bempikibart clinical…
Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B
Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in…
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical…
Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered…
Recce Pharmaceuticals advances R327 Gel towards Phase 3 after promising Phase II trial
Recce Pharmaceuticals Limited has announced significant success in its Phase II trial of RECCE 327 topical gel (R327G),…
Wockhardt’s Zaynich achieves record-breaking 96.8% clinical cure rate in cUTI Phase III trial
Wockhardt Limited has announced a major breakthrough in the treatment of complicated urinary tract infections (cUTI) with its…